Medical researchers from Tulane University asked 105 patients treated with somatostatin analogue (SSA) and 49 healthcare professionals about their acromegaly treatment experience and satisfaction. The results may surprise you. Take the quiz below and see if you agree.
Geer EB, Sisco J, Adelman DT, et al. Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider [published online ahead of print, 2019 Dec 5].Pituitary. 2019; doi:10.1007/s11102-019-01013-2.
Get news about resources and treatment options for acromegaly.
1. Geer EB, Sisco J, et al. Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary. 2019 December 5. (doi:10.1007/s11102-019-01013-2) 2. Strasburger CJ, Karavitaki, N, et al. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. European Journal of Endocrinology, 2016. (doi:10.1530/EJE-15-1042) 3. Liu S, Adelman DT, et al. Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. Journal of Investigative Medicine. 2017. (doi:10.1136/jim-2017-000570) 4. Biermasz N. New medical therapies on the horizon: oral octreotide. Pituitary. 2017. (doi:10.1007/s11102-016-0785-3) 5. Fleseriu M, Fogelfeld L, et al. Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary. 2019. (doi:10.1007/s11102-019-00986-4)